Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis.

Wollmann BM, Syversen SW, Vistnes M, Lie E, Mehus LL, Molden E.

Drug Metab Dispos. 2018 Jul 10. pii: dmd.118.082065. doi: 10.1124/dmd.118.082065. [Epub ahead of print]

PMID:
29991576
2.

Hvem bør få klopidogrel etter hjerneslag?

Ihle-Hansen H, Hagberg G, Molden E, Myrstad M.

Tidsskr Nor Laegeforen. 2018 May 28;138(9). doi: 10.4045/tidsskr.18.0277. Print 2018 May 29. Norwegian. No abstract available.

PMID:
29808656
Free Article
3.

Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.

Gjestad C, Haslemo T, Andreassen OA, Molden E.

Br J Clin Pharmacol. 2018 Jul;84(7):1624-1625. doi: 10.1111/bcp.13606. Epub 2018 May 10. No abstract available.

PMID:
29749106
4.

Serumkonsentrasjonsmålinger av DOAK-legemidler.

Dyrkorn R, Lundgaard H, Stokes CL, Molden E, Spigset O.

Tidsskr Nor Laegeforen. 2018 Apr 17;138(7). doi: 10.4045/tidsskr.18.0237. Print 2018 Apr 17. Norwegian. No abstract available.

PMID:
29663756
Free Article
5.

Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker.

Hole K, Wollmann BM, Nguyen C, Haslemo T, Molden E.

Ther Drug Monit. 2018 Aug;40(4):463-468. doi: 10.1097/FTD.0000000000000518.

PMID:
29649093
6.

Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.

Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop S, Cameron D, Hamshere ML, Han J, Hubbard L, Lynham A, Mantripragada K, Rees E, MacCabe JH, McCarroll SA, Baune BT, Breen G, Byrne EM, Dannlowski U, Eley TC, Hayward C, Martin NG, McIntosh AM, Plomin R, Porteous DJ, Wray NR, Caballero A, Geschwind DH, Huckins LM, Ruderfer DM, Santiago E, Sklar P, Stahl EA, Won H, Agerbo E, Als TD, Andreassen OA, Bækvad-Hansen M, Mortensen PB, Pedersen CB, Børglum AD, Bybjerg-Grauholm J, Djurovic S, Durmishi N, Pedersen MG, Golimbet V, Grove J, Hougaard DM, Mattheisen M, Molden E, Mors O, Nordentoft M, Pejovic-Milovancevic M, Sigurdsson E, Silagadze T, Hansen CS, Stefansson K, Stefansson H, Steinberg S, Tosato S, Werge T; GERAD1 Consortium:; CRESTAR Consortium:, Collier DA, Rujescu D, Kirov G, Owen MJ, O'Donovan MC, Walters JTR; GERAD1 Consortium; CRESTAR Consortium; GERAD1 Consortium; CRESTAR Consortium.

Nat Genet. 2018 Mar;50(3):381-389. doi: 10.1038/s41588-018-0059-2. Epub 2018 Feb 26.

7.

Correction: Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.

Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O.

PLoS One. 2018 Jan 16;13(1):e0191508. doi: 10.1371/journal.pone.0191508. eCollection 2018.

8.

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.

Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M.

Am J Psychiatry. 2018 May 1;175(5):463-470. doi: 10.1176/appi.ajp.2017.17050550. Epub 2018 Jan 12.

PMID:
29325448
9.

Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015.

Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, Granas AG, Johannessen SI, Landmark CJ.

Epilepsy Res. 2018 Jan;139:35-42. doi: 10.1016/j.eplepsyres.2017.11.001. Epub 2017 Nov 11.

PMID:
29175562
10.

Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy.

Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jørgensen KN, Melle I, Andreassen OA, Molden E, Jönsson EG.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:263-271. doi: 10.1016/j.pnpbp.2017.11.004. Epub 2017 Nov 7.

PMID:
29122637
11.

Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.

Solhaug V, Molden E.

Scand J Pain. 2017 Oct;17:193-200. doi: 10.1016/j.sjpain.2017.09.009. Epub 2017 Oct 17. Review.

PMID:
29054049
12.

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E.

CNS Drugs. 2017 Nov;31(11):991-997. doi: 10.1007/s40263-017-0469-1.

PMID:
28948574
13.

Recovery of CYP3A Phenotype after Kidney Transplantation.

Hole K, Størset E, Olastuen A, Haslemo T, Kro GB, Midtvedt K, Åsberg A, Molden E.

Drug Metab Dispos. 2017 Dec;45(12):1260-1265. doi: 10.1124/dmd.117.078030. Epub 2017 Sep 19.

PMID:
28928137
14.

Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.

Kringen MK, Chalabianloo F, Bernard JP, Bramness JG, Molden E, Høiseth G.

Ther Drug Monit. 2017 Oct;39(5):550-555. doi: 10.1097/FTD.0000000000000437.

PMID:
28723731
15.

Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.

Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O.

PLoS One. 2017 Jul 14;12(7):e0181082. doi: 10.1371/journal.pone.0181082. eCollection 2017. Erratum in: PLoS One. 2018 Jan 16;13(1):e0191508.

16.

Hvis du skal gjøre det, gjør det riktig!

Solberg DK, Refsum H, Molden E.

Tidsskr Nor Laegeforen. 2017 Jun 26;137(12-13):854. doi: 10.4045/tidsskr.17.0441. Print 2017 Jun 27. Norwegian. No abstract available.

PMID:
28655243
Free Article
17.

Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition.

Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O.

Clin Pharmacol Ther. 2018 Mar;103(3):477-484. doi: 10.1002/cpt.770. Epub 2017 Sep 19.

18.

4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.

Gjestad C, Haslemo T, Andreassen OA, Molden E.

Br J Clin Pharmacol. 2017 Nov;83(11):2398-2405. doi: 10.1111/bcp.13341. Epub 2017 Jul 21.

PMID:
28585378
19.

Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A.

Br J Clin Pharmacol. 2017 Jun;83(6):1357-1358. doi: 10.1111/bcp.13276. Epub 2017 Apr 3. No abstract available.

20.
21.

Psychotropics and weak opioid analgesics in plasma samples of older hip fracture patients - detection frequencies and consistency with drug records.

Waade RB, Molden E, Martinsen MI, Hermann M, Ranhoff AH.

Br J Clin Pharmacol. 2017 Jul;83(7):1397-1404. doi: 10.1111/bcp.13244. Epub 2017 Mar 9.

22.

Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway.

Westin AA, Brekke M, Molden E, Skogvoll E, Aadal M, Spigset O.

BMJ Open. 2017 Mar 1;7(3):e015738. doi: 10.1136/bmjopen-2016-015738.

23.

The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A.

Br J Clin Pharmacol. 2017 Jul;83(7):1457-1465. doi: 10.1111/bcp.13248. Epub 2017 Feb 27.

24.

Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome.

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Johannessen Landmark C.

Epilepsy Res. 2017 Jan;129:125-131. doi: 10.1016/j.eplepsyres.2016.12.001. Epub 2016 Dec 5.

PMID:
28043062
25.

Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A.

Br J Clin Pharmacol. 2017 Jun;83(6):1350-1352. doi: 10.1111/bcp.13188. Epub 2016 Dec 22. No abstract available.

26.

4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.

Wollmann BM, Syversen SW, Lie E, Gjestad C, Mehus LL, Olsen IC, Molden E.

Clin Transl Sci. 2017 Jan;10(1):42-49. doi: 10.1111/cts.12431. Epub 2016 Nov 5.

27.

Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.

Hole K, Gjestad C, Heitmann KM, Haslemo T, Molden E, Bremer S.

Eur J Clin Pharmacol. 2017 Mar;73(3):317-324. doi: 10.1007/s00228-016-2178-y. Epub 2016 Dec 14.

PMID:
27975131
28.

[Safer treatment with serum concentration monitoring of the new anticoagulants?].

Lundgaard H, Dyrkorn R, Stokes CL, Molden E, Spigset O.

Tidsskr Nor Laegeforen. 2016 Oct 11;136(18):1556-1560. eCollection 2016 Oct. Norwegian. No abstract available.

29.

Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.

Smith RL, Haslemo T, Refsum H, Molden E.

Eur J Clin Pharmacol. 2016 Sep;72(9):1099-104. doi: 10.1007/s00228-016-2087-0. Epub 2016 Jun 29.

PMID:
27353638
30.

Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.

Molden E, Waade RB, Hoff M, Haslemo T.

Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):470-475. doi: 10.1111/bcpt.12614. Epub 2016 May 31.

31.

[Genetically determined variation in bioactivation of tamoxifen and clopidogrel].

Solhaug V, Molden E.

Tidsskr Nor Laegeforen. 2016 Mar 15;136(5):434-6. doi: 10.4045/tidsskr.15.0555. eCollection 2016 Mar 15. Norwegian. No abstract available.

32.

Effect of teaching and checklist implementation on accuracy of medication history recording at hospital admission.

Lea M, Barstad I, Mathiesen L, Mowe M, Molden E.

Int J Clin Pharm. 2016 Feb;38(1):20-4. doi: 10.1007/s11096-015-0218-9. Epub 2015 Nov 20.

PMID:
26589204
33.

4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?

Gjestad C, Huynh DK, Haslemo T, Molden E.

Br J Clin Pharmacol. 2016 Feb;81(2):269-76. doi: 10.1111/bcp.12833. Epub 2015 Dec 26.

34.

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.

Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E.

Ther Drug Monit. 2016 Feb;38(1):127-34. doi: 10.1097/FTD.0000000000000251.

PMID:
26418700
35.

Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.

Høiseth G, Haslemo T, Uthus LH, Molden E.

Ther Drug Monit. 2015 Oct;37(5):589-93. doi: 10.1097/FTD.0000000000000183.

PMID:
25565674
36.

Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.

Hermann M, Waade RB, Molden E.

Ther Drug Monit. 2015 Aug;37(4):546-9. doi: 10.1097/FTD.0000000000000169.

PMID:
25565671
37.

Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.

Bakken GV, Molden E, Hermann M.

Ther Drug Monit. 2015 Apr;37(2):256-61. doi: 10.1097/FTD.0000000000000135.

PMID:
25254417
38.

Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.

Waade RB, Hermann M, Moe HL, Molden E.

Eur J Clin Pharmacol. 2014 Aug;70(8):933-40. doi: 10.1007/s00228-014-1696-8. Epub 2014 May 27.

PMID:
24858822
39.

No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.

Söderberg MM, Molden E, Dahl ML.

Pharmacogenet Genomics. 2014 May;24(5):272-5. doi: 10.1097/FPC.0000000000000041.

PMID:
24595013
40.

More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K.

Transplantation. 2014 Jun 27;97(12):1266-71. doi: 10.1097/01.TP.0000443225.66960.7e.

41.

Anticholinergic activity in cerebrospinal fluid and serum in individuals with hip fracture with and without delirium.

Watne LO, Hall RJ, Molden E, Raeder J, Frihagen F, MacLullich AM, Juliebø V, Nyman A, Meagher D, Wyller TB.

J Am Geriatr Soc. 2014 Jan;62(1):94-102. doi: 10.1111/jgs.12612. Epub 2014 Jan 2.

PMID:
24383557
42.

Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.

Hendset M, Molden E, Knape M, Hermann M.

Ther Drug Monit. 2014 Feb;36(1):80-5. doi: 10.1097/FTD.0000000000000018.

PMID:
24232129
43.

Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs.

Kersten H, Wyller TB, Molden E.

Ther Drug Monit. 2014 Feb;36(1):125-30. doi: 10.1097/FTD.0b013e31829da990.

PMID:
24089073
44.

Pharmacist-initiated management of antagonistic interactions between anticholinergic drugs and acetyl cholinesterase inhibitors in individuals with dementia.

Efjestad AS, Molden E, Oksengård AR.

J Am Geriatr Soc. 2013 Sep;61(9):1624-5. doi: 10.1111/jgs.12431. No abstract available.

PMID:
24028363
45.

Severity and management of drug-drug interactions in acute geriatric patients.

Lea M, Rognan SE, Koristovic R, Wyller TB, Molden E.

Drugs Aging. 2013 Sep;30(9):721-7. doi: 10.1007/s40266-013-0091-y.

PMID:
23681400
46.

Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.

Söderberg MM, Haslemo T, Molden E, Dahl ML.

Pharmacogenet Genomics. 2013 May;23(5):279-85. doi: 10.1097/FPC.0b013e3283602876.

PMID:
23492908
47.

Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.

Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, Hjelmesæth J, Andersson TB, Sandbu R, Christensen H.

Clin Pharmacol Ther. 2013 Mar;93(3):275-82. doi: 10.1038/clpt.2012.261. Epub 2012 Dec 27. Erratum in: Clin Pharmacol Ther. 2015 Apr;97(4):428.

PMID:
23361102
48.

Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.

Söderberg MM, Haslemo T, Molden E, Dahl ML.

Pharmacogenomics J. 2013 Dec;13(6):544-50. doi: 10.1038/tpj.2012.47. Epub 2012 Nov 13.

PMID:
23147717
49.

Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial.

Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB.

J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):271-8. doi: 10.1093/gerona/gls176. Epub 2012 Sep 14.

PMID:
22982689
50.

Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking.

Haslemo T, Olsen K, Lunde H, Molden E.

Ther Drug Monit. 2012 Oct;34(5):512-7. doi: 10.1097/FTD.0b013e3182693d2a.

PMID:
22972535

Supplemental Content

Loading ...
Support Center